Title: Chemotherapy of Medulloblastoma
1Chemotherapy of Medulloblastoma
2Objectives
- Briefly describe chemotherapy of medulloblastoma
- Discuss different regimens used for therapy and
their mechanisms, administrations, how they are
supplied, dosages for certain drugs, and side
effects - Relate therapy to Jorge P.
- Conclusion
3Overview of chemotherapy of medulloblastoma
- At this time, the role of chemotherapy in
medulloblastoma is primarily an additional
treatment following surgery and radiation - For average-risk disease, children from 3-10 who
received chemotherapy and radiation had a
superior survival rate - 3 year progression free survival rate 80
4Regiments used in chemotherapy
- Methotrexate tablets, powder/solution for
injection folate antimetabolite - Lomustine (CCNU) - capsule an oral nitrosurea
alkylating agent - Etoposide solution for injection cell
cycle-phase specific antineoplastic agent - Vincristine solution for injection
plant-derived vinca alkaloid which is extracted
from Catharanthus rosea - Cyclophosphamide tablets or powder for
injection bifunctional alkylating agent related
to nitrogen mustard - Cisplatin solution for injection planar
platinum bifunctional alkylating agent - Carboplatin powder/solution for injection
platinum compound related to cisplatin, less
cytotoxic
5Details of methotrexate
- Mechanism of action
- Competitively inhibits dihydrofolate reductase
- Interferes with DNA/RNA synthesis
- Cell cycle-specific (S-phase or G1 into S-phase)
- Administration
- - Intravenously, orally, intraventricularly
(Jorge P.), intrathecally, intramuscularly - Dosing
- Intraventricular dosing guidelines do not exist,
however in children 2mg/day is commonly used
(Jorge P.) - Side Effects
- - Severe changes in vision, diarrhea, confusion
- - Mild Hair loss, nausea, eye irritation
http//redpoll.pharmacy.ualberta.ca/drugbank/drugB
ank/PC_IMAGE/APRD00353_ZOOM.gif
6Details of lomustine (CCNU)
- Mechanism of action
- Inhibits DNA replication, RNA transcription, and
nucleic acid function - The chloroethyl group alkylates nucleic acids and
cell proteins to form DNA-DNA or DNA-protein
crosslinks - Administration
- Orally
- Side effects
- - Severe difficulty breathing, low blood count,
signs of infection - - Mild confusion, hair loss, loss of appetite
http//redpoll.pharmacy.ualberta.ca/drugbank/drugB
ank/PC_IMAGE/APRD00292_ZOOM.gif
7Details of etoposide
- Mechanism of action
- - Active during G2
- - Binds to a complex of DNA and topoisomerase II
- - Apoptosis
- Administration
- - Orally or intravenously
- Side Effects
- - Severe tarry stools, blood in urine,
difficulty breathing - - Mild diarrhea, hair loss, headache
http//redpoll.pharmacy.ualberta.ca/drugbank/drugB
ank/PC_IMAGE/APRD00239_ZOOM.gif
8Details of vincristine
- Mechanism of action
- - Binds to the alpha, beta sites of tubulin
- Interferes with microtubules which compose
mitotic spindle fibers - Cell cycle arrest in metaphase
- Administration
- - Intravenously
- Dosing
- - 1.5 mg/m2 BSA
- - For Jorge P, his BSA is 0.61 m2 so he would
get (0.61 m2 1.5mg/m2 0.915 mg/day - Side effects
- - Severe constipation, fever, rash
- - Mild hair loss, loss of appetite, feeling tired
http//redpoll.pharmacy.ualberta.ca/drugbank/drugB
ank/PC_IMAGE/APRD00495_ZOOM.gif
9Details of cyclophosphamide
- Mechanism of action
- Prodrug that requires hepatic activation in order
to be cytotoxic - Activated in liver by cytochrone P450 enzymes
- Phosphoramide mustard is the active moiety
- Forms intrastrand and interstrand DNA-DNA
crosslinks. - Administration
- - Orally or intravenously
- Dosing
- - 800 mg/m2 BSA
- - For Jorge P. (0.61 m2 800 mg/m2 488
mg/dose) - Side effects
- - Severe blood in urine, signs of infection,
confusion - - Mild decreased appetite, hair loss, muscle
pains
http//redpoll.pharmacy.ualberta.ca/drugbank/drugB
ank/PC_IMAGE/APRD00408_ZOOM.gif
10Details of cisplatin
- Mechanism of action
- Intracellularly, loses its chloride groups making
it electrophilic. - Forms interstrand/intrastrand DNA RNA
crosslinks - Administration
- - Intravenously or intraarterially
- Side effects
- - Severe difficulty breathing, hearing loss,
nausea and vomiting - - Mild blurred vision, changes in taste, loss of
appetite
http//redpoll.pharmacy.ualberta.ca/drugbank/drugB
ank/PC_IMAGE/APRD00359_ZOOM.gif
11Details of carboplatin
- Mechanism of action
- Hydroxylated by water to form the active
compound, slower than cisplatin. - Works like other bifunctional alkylating agents
- Administration
- - Intravenously
- Side effects
- - Severe changes in eyesight, hearing loss,
difficulty breathing - - Mild fatigue, loss of appetite, loss of hair,
metallic taste
http//redpoll.pharmacy.ualberta.ca/drugbank/drugB
ank/PC_IMAGE/APRD00466_ZOOM.gif
12Jorge P.
- Methotrexate
- - 2mg/day
- Cyclophosphamide
- - 488 mg/dose
- Vincristine
- - 0.915 mg/dose
13Conclusion
- Chemotherapy usually used after radiation or
surgical therapy - Wide variety of different regimens used each with
different dosages, administrations, and side
effects - Jorge P was administered methotrexate,
vincristine, and cyclophosphamide
14References
- Oncolink. 1994. Abraham Cancer Center of the
University of Pennsylvania. 1 March 2007
http//www.oncolink.org/types/article.cfm?c14s7
8ss783id9484 - Mcdonald T., MD. Emedicine. 21 July 2006. Web
MD. 1 March 2007. http//www.emedicine.com/ped/t
opic1396.htm - Clinical Pharmacology. CD-ROM. Tampa Gold
Standard, 1994-2005 - DrugBank. February 1, 2006. Genome Alberta
Genome Canada and Departments of Computing
Science Biological Sciences at the University
of Alberta. 1 March 2006. http//redpoll.pharmacy
.ualberta.ca/drugbank/